Posted by Michael Wonder on 22 Aug 2022
Kyowa Kirin receives European Commission approval for use of Crysvita (burosumab) for the treatment of tumour-induced osteomalacia
19 August 2022 - Crysvita is the first approved biologic treatment in the EU for patients with tumour-induced osteomalacia who cannot undergo surgical removal of tumours.
Kyowa Kirin today announced that the European Commission approved Crysvita (burosumab) for the treatment of FGF23-related hypophosphataemia in tumour-induced osteomalacia associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.
